Disease-Modifying Antirheumatic Drug (DMARD) Market
A increase in the number of research project launches is one of the key market trends projected to boost growth over the forecast period. RINVOQ, for instance, was given FDA approval in April 2022 to treat patients with active ankylosing spondylitis (AS) who had an adverse response to or intolerance to one or more TNF blockers.
Click Here for Free Sample Copy (Use corporate email ID Get Higher Priority) @ https://www.coherentmarketinsights.com/insight/request-sample/5185
Impact of Coronavirus
Key industry stakeholders were affected by the COVID-19 pandemic’s significant interruptions to clinical trial execution in the United States. An upheaval in the investigative site’s capabilities was brought on by staff layoffs, social-distance protocols, financial losses, and patient safety worries. In order to facilitate drug development, sponsors, CROs, and other companies have turned to remote working environments. The COVID-19 pandemic is thought to have forced the termination or interruption of 80% of non-COVID-19 studies. According to a study released in April 2020 by Medidata, a life sciences software company that supports clinical trials with a primary focus on evidence generation, investigative sites showed flexibility and innovation in embracing new approaches to deal with the challenges posed by the pandemic, with more than half of investigative sites switching to virtual approaches to interact with patients. According to follow-up tests conducted in August 2020, the COVID-19 pandemic continues to have an impact on existing trials and the beginning of new trials, with more than 60% of respondents indicating an average or greater level of impact. Challenges with patient recruiting and enrollment were especially mentioned by respondents. The U.S. FDA recently stated that the impact of COVID-19 may compel organisations conducting clinical trials to explore virtual patient visits or implement new processes in lieu of existing protocols. The FDA guideline was released in March 2020 and amended in July 2020. As a result, there are additional possibilities for employing remote healthcare, such as running virtual or decentralised studies, using site-less clinical trials, or using other unconventional strategies that do not require in-person visits.
Key Players
Cumberland Pharmaceuticals Inc., Sanofi, Gilead Sciences, Inc., Pfizer, UCB S.A., Eli Lilly & Company, Bristol-Myers Squibb Company, Johnson & Johnson, Swedish Orphan Biovitrum AB, AbbVie Inc. are important market participants.
Furthermore, during the course of the projected period, the prevalence of psoriatic arthritis is anticipated to rise. Among instance, the combined prevalence for children and adolescents (under the age of 18) was 3.3% in 2018, according to statistics released in the National Center for Biotechnology Information in January 2019. The prevalence of psoriatic arthritis (PsA) was 22.7% in psoriasis patients from Europe, 21.5% in psoriasis patients from South America, 19.5% in psoriasis patients from North America, 15.5% in psoriasis patients from Africa, and 14.0% in psoriasis patients from Asia.
𝐖𝐞 𝐎𝐟𝐟𝐞𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐂𝐥𝐢𝐜𝐤 @ https://www.coherentmarketinsights.com/insight/request-customization/5185
Key Takeaways
The worldwide market for disease-modifying antirheumatic drugs (DMARD) is expected to expand at a CAGR of 3.5% over the course of the forecast period as more rheumatoid arthritis products get approved. For instance, the U.S. Food and Drug Administration (FDA) approved the once-daily oral pharmaceutical OLUMIANT (baricitinib) in June 2018 for the treatment of people with moderately to highly active rheumatoid arthritis (RA) who have not responded well to one or more TNF inhibitor drugs.
Due to rising hospitalisation rates for systemic lupus erythematosus, hospital pharmacies are anticipated to have a leading position in the worldwide market for disease-modifying antirheumatic drugs (DMARD) throughout the forecast period. For instance, the mean crude hospitalisation rate for systemic lupus erythematosus (SLE) assessed in 2020 in the United Arab Emirates was 29.8%, according to data released by PubMed in January 2021. Pregnancy (29%), SLE activity (24%), and infection (20%) were the top causes of hospitalisation. When main and secondary causes are included, the percentage of hospitalizations resulting from SLE activity climbed to 32 in the UAE in 2020.
Due to key market players concentrating on inorganic growth strategies like licencing agreements for disease-modifying antirheumatic drugs, Asia Pacific is predicted to have the highest CAGR among all regions in the global market for disease-modifying antirheumatic drugs (DMARD) over the forecast period. For instance, the well-known, innovation-driven specialty pharma company China Medical System Holdings Ltd. (CMS), with a focus on sales and marketing in China, announced in June 2019 that one of its wholly owned subsidiaries had entered into a licencing agreement with a subsidiary of Sun Pharmaceutical Industries Ltd. (SPI), an Indian multinational pharmaceutical company, for the creation and marketing of Tildrakizumab in Greater China as a novel biologic treatment for psoriasis and psoriatic arthritis (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan)
Cumberland Pharmaceuticals Inc., Sanofi, Pfizer, Gilead Sciences, Inc., Hoffman-La Roche AG, UCB S.A., Johnson & Johnson, Bristol-Myers Squibb Company, AbbVie Inc., Swedish Orphan Biovitrum AB, Eli Lilly & Company, and Amgen Inc., are significant market participants in the global disease-modifying antirheumatic drug (DMARD) market.
Avail Discount on various license types on Immediate Purchase @ https://www.coherentmarketinsights.com/insight/buy-now/5185
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Drug Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Pipeline Analysis
- Market Dynamics
- Global Disease-Modifying Antirheumatic Drug (DMARD) Market– Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Demand and Supply
- COVID-19 Impact Assessments
- Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Synthetic (sDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Conventional synthetic (csDMARDs)
- Targeted synthetic DMARDs (tsDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Biological DMARDs (bDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Introduction
- Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Route of Drug Administration, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Introduction
- Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Indication, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Systemic Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Introduction
- Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Distribution Channel, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/disease-modifying-antirheumatic-drug-market-4474
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837